Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of SY-004 in Type 2 Diabetes Mellitus
NCT04217291Phase 2Completed
- Sponsor
- Yabao Pharmaceutical Group Co., Ltd.
- Start
- Dec 2019
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of globalagliatin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Yabao Pharmaceutical Group Co., Ltd. Primary endpoint: Changes in Glycosylated Hemoglobin A1c at 16 weeks. Started Dec 2019; status: completed.
02
Drugs
globalagliatin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04217291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04217291.